The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer.
S. A. Szyldergemajn
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
A. Gonçalves
No relevant relationships to disclose
J. P. Metges
No relevant relationships to disclose
K. Gunzer
No relevant relationships to disclose
C. Montagut
No relevant relationships to disclose
R. Salazar
No relevant relationships to disclose
M. Alsina
No relevant relationships to disclose
T. R. J. Evans
Research Funding - PharmaMar
D. Swinson
No relevant relationships to disclose
R. D. Petty
No relevant relationships to disclose
H. Singer
Employment or Leadership Position - PharmaMar
C. M. Kahatt
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar